次世代がん診断薬市場：技術、がんタイプ、用途、機能別-2024-2030年の世界予測

次世代がん診断薬市場規模は2023年に97億7,000万米ドルと推定され、2024年には120億2,000万米ドルに達し、CAGR 24.12％で2030年には443億6,000万米ドルに達すると予測されます。

調査手法には、がんの検出と特徴付けに利用されるツール、技術、方法論における最新の技術進歩が含まれます。この市場は、従来の診断方法と比較して精度、感度、特異性を向上させる技術革新に焦点を当てています。早期発見、予後予測、がん治療モニタリングのためのゲノム、プロテオミクス、エピゲノム解析、イメージング技術、バイオインフォマティクスツールなどが含まれます。次世代がん診断薬の拡大には、世界のがん罹患率の増加、ゲノムシーケンス技術の進歩、個別化医療の重視の高まりなど、いくつかの要因があります。さらに、がん研究に対する政府の取り組みや資金提供は、市場の成長に大きく貢献しています。人工知能と機械学習を診断に組み込むことで、がんの発見と予後の精度を高める機会ももたらされます。有望な市場開拓にもかかわらず、次世代がん診断薬市場はいくつかの限界と課題に直面しています。高度な診断技術に関連する高額なコストは、特に中低所得国において、こうしたツールへのアクセスを制限する可能性があります。さらに、がん生物学の複雑さと腫瘍の種類の多様性は、普遍的に有効な診断ソリューションを開発する上での課題となっています。規制上のハードルや確固たる臨床検証の必要性も、市場の技術革新のペースを遅らせています。しかし、リキッドバイオプシー、循環腫瘍DNA（ctDNA）分析、非侵襲的イメージング技術などの最近の発展により、がんの早期発見とモニタリングに新たな道が開かれつつあります。これらの進歩は市場成長の大きな機会となっています。さらに、がん診断における次世代シーケンサー（NGS）の応用は進化を続けており、新規バイオマーカーや治療標的を発見する可能性を提供しています。

テクノロジーがんに関連する変異を特定する分子診断の需要が高まる

Clustered regularly interspaced short palindromic repeats診断技術は、遺伝子編集機能を活用してがんの突然変異を正確に検出する、がん診断への革命的なアプローチを提示します。この技術は、迅速で正確、かつ費用対効果の高い診断の可能性を提供し、がんの同定と治療の方法を根本的に変えます。DNAマイクロアレイは、1回の実験で数千のDNA配列の同時解析を可能にします。この技術は、がん診断において、異なるがん種に特異的な遺伝子変異や発現を同定するために使用され、個別化された治療計画を促進します。Lab-on-a-chipは、複数の検査工程を1つのチップに統合し、がん診断のためのコンパクトで効率的なソリューションを提供します。遺伝子発現を測定する方法であるRT-PCRと組み合わせることで、分子レベルでがんマーカーを検出・定量するための強力なツールとなります。分子診断学では、DNAやRNAの塩基配列を解析し、がんに関連する変異を同定します。この分野では、がんの早期発見、分類、管理における遺伝子解析の重要性を強調し、オーダーメイドの治療アプローチを提供しています。NGSは、数百万個のDNA断片を並行して配列決定することにより、包括的なゲノム・プロファイリングを提供します。この技術により、がんの原因となる遺伝子変異に関する深い洞察が得られ、標的治療の特定と患者の予後改善が可能になります。タンパク質マイクロアレイは、タンパク質の発現と相互作用を大規模に解析します。がん診断では、がんによって引き起こされるタンパク質の変化を研究するために使用され、早期発見や治療戦略のための新しいバイオマーカーの発見に役立っています。定量的ポリメラーゼ連鎖反応（qPCR）は、標的とするDNA分子を増幅し定量する技術です。複数の分析対象を同時に測定するマルチプレキシングにより、がん診断におけるqPCRの能力が強化され、1回の検査でがんに関連する複数の遺伝子を検出することができます。

応用例がん治療の効果を追跡するための治療モニタリングにおける診断ツールの展開

がん検診は、がんと闘うための最初の防衛ラインであり、次世代診断技術を活用して、明らかな症状のない人のがんの存在を特定します。この分野では、がんの早期発見に重点を置き、治療が成功しやすい段階で病気を診断することを目指しています。高度な画像診断技術、分子診断、バイオマーカー評価は、がんスクリーニングの有効性を高めるために使用されるツールです。コンパニオン診断薬は、標的治療の恩恵を受ける可能性が最も高い患者を特定するためにデザインされた特殊な検査です。この分野は、標的治療に対する患者の反応性を予測する特定の遺伝子マーカーや分子マーカーの存在を判定することで、個別化医療において重要な役割を果たしています。次世代がん診断薬の文脈では、治療戦略を個人のがんに合わせて調整するためにゲノム・プロファイリングを使用することが多いです。次世代がん診断薬の予後予測ツールは、診断された患者のがんの経過と転帰を予測するために使用されます。この分野は、疾患の侵襲性、再発のリスク、全生存期間の予測を評価するのに役立ちます。高度なゲノムおよびプロテオーム解析を活用することで、予後診断薬は治療介入の必要性や強度に関する情報に基づいた意思決定を支援し、最終的に患者の管理計画を導く。次世代がん診断薬におけるリスク解析は、遺伝的、環境的、ライフスタイル的要因に基づく個人のがん発症リスクの評価に焦点を当てています。この分野では、さまざまな遺伝子検査やバイオマーカー評価法を利用して、特定のがんを発症するリスクが高い個人を特定し、的を絞った予防対策やより頻繁で詳細なサーベイランス・プログラムにつなげる可能性があります。治療モニタリングでは、次世代診断ツールを用いてがん治療の効果を追跡し、疾患の進行や再発の兆候を監視します。この応用分野は、治療計画をリアルタイムで調整し、副作用を管理し、患者の転帰を改善するために極めて重要です。循環腫瘍DNA（ctDNA）、画像技術、その他のバイオマーカーの利用により、治療モニタリングは治療に対する腫瘍の反応に関する詳細な洞察を提供し、個別化された治療調整を促進します。

地域別の洞察

米国を中心とする南北アメリカでは、研究開発への多額の投資によって急速な進歩を遂げています。主に精密医療と、循環腫瘍DNAを検出するリキッドバイオプシーなどの非侵襲的診断技術に焦点が当てられています。EMEA地域は、次世代がん診断薬の採用と開発において多様な状況を示しています。欧州は、強力なヘルスケアシステムと公的医療政策に支えられ、ゲノム配列決定とバイオマーカー分析を標準的ながん治療に組み込んでいる国がいくつかあり、同地域をリードしています。中東、特にイスラエルやアラブ首長国連邦などの国々は、がん診断を含む医療技術の革新的な拠点として急速に台頭しています。アフリカは、資源の制約など、より多くの課題に直面しているが、国際的なパートナーシップや、がん医療のインフラとアクセシビリティを向上させる取り組みを通じて前進しています。アジア太平洋地域は、がん罹患率の上昇、ヘルスケア支出の増加、がんの早期発見に対する意識の高まりなどを背景に、次世代がん診断薬市場において著しい成長を遂げています。日本、韓国、中国、オーストラリアが最前線で、ヘルスケア技術や研究に多額の投資を行っています。特に中国では、AIを活用した診断ツールなどの技術が急速に進歩し、高い採用率を示しています。その他の特典として、この地域は急成長中のバイオテクノロジー新興企業や、がん診断薬を地域の特性に合わせて調整することを目的とした世界企業と地元企業との戦略的提携の恩恵を受けています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、次世代がん診断薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、次世代がん診断薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.次世代がん診断薬市場の市場規模および予測は？

2.次世代がん診断薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.次世代がん診断薬市場の技術動向と規制枠組みは？

4.次世代がん診断薬市場における主要ベンダーの市場シェアは？

5.次世代がん診断薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的にがん患者数が増加し、効率的な診断の必要性が高まっている
    • がん治療におけるマイクロ流体チップの利用拡大
    • がん検診に向けた政府の取り組み
  • 抑制要因
    • 診断への多額の投資と不十分な標準化
  • 機会
    • 個別化・高度ゲノム医療の普及
    • 次世代がん診断薬における技術的進歩
  • 課題
    • NGC診断に伴う制限とリスク
• 市場セグメンテーション分析
  • テクノロジー：がんに関連する変異を特定するための分子診断の需要が増加
  • 応用：がん治療の有効性を追跡するための治療モニタリング全体にわたる診断ツールの導入
• 市場動向分析
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析
• 顧客のカスタマイズ

第6章 次世代がん診断薬市場：技術別

• クラスター化された規則的な間隔を置いた短い回文反復の診断
• DNAマイクロアレイ
• ラボオンチップと逆転写PCR
• 分子診断
• 次世代シーケンシング
• タンパク質マイクロアレイ
• qPCRとマルチプレックス

第7章 次世代がん診断薬市場がんの種類別

• 膀胱がん
• 乳がん
• 子宮頸がん
• 大腸がん
• 腎臓がん
• 肺がん
• 膵臓がん
• 前立腺がん
• 甲状腺がん
• 子宮がん

第8章 次世代がん診断薬市場：用途別

• がん検診
• コンパニオン診断
• 予測
• リスク分析
• 治療モニタリング

第9章 次世代がん診断薬市場：機能別

• バイオマーカー開発
• CTC分析
• エピジェネティック解析
• 遺伝子解析
• プロテオーム解析

第10章 南北アメリカの次世代がん診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の次世代がん診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの次世代がん診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • ジェニアリス、バイオマーカーベースのがん診断モデルを開発
  • サーモフィッシャーサイエンティフィックとアーセナルバイオサイエンスが協力し、自己T細胞療法の臨床製造をサポート
  • ファイザー、シーゲンを430億米ドルで買収し腫瘍学に重点を移す
  • アイベックスとアルバーノ・ラボラトリーズ、がん診断のためのAIの複数年、複数組織拡張契約を締結
  • スウォンジーのバイオテクノロジー新興企業、AI大腸がん血液検査のために150万ポンドを調達
  • 医療のための精密医療次世代スクリーニングによる精密腫瘍学の加速と新たながん診断のサポート

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. NEXT-GENERATION CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. NEXT-GENERATION CANCER DIAGNOSTICS MARKET DYNAMICS
• FIGURE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. NEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON-A-CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON-A-CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THYROID CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 66. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 67. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 68. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 79. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 80. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 81. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 82. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 83. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 84. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 85. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 86. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 87. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 88. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 89. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 90. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 91. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 92. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 93. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 94. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 95. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 96. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 97. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 98. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 99. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 100. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 101. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 102. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 103. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 104. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 105. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 106. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 107. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 108. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 109. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 110. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 111. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 112. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 113. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 114. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 115. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 116. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 117. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 118. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 119. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 120. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 121. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 122. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 123. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 124. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 125. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 126. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 127. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 128. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 129. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 130. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 131. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 132. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 133. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 134. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 135. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 136. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 137. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 138. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 139. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 140. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 141. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 142. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 143. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 144. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 145. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 146. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 147. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 148. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 149. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 150. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 151. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 152. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 153. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 154. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 155. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 156. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 157. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 158. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 159. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 160. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 161. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 162. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 163. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 164. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 165. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 166. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 167. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 168. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 169. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 170. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 171. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 172. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 173. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 174. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 175. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 176. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 177. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 178. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 179. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 180. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 181. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 182. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 183. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 184. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 185. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 186. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 187. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 188. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 189. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 190. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 191. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 192. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 193. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 194. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 195. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 196. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 197. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 198. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 199. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 200. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 201. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 202. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 203. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 204. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 205. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 206. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 207. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 208. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 209. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 210. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 211. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 212. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 213. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 214. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 215. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 216. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 217. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 218. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 219. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 220. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 221. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 222. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 223. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 224. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 225. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 226. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 227. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 228. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 229. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 230. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 231. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 232. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 233. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 234. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 235. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 236. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 237. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 238. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 239. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 240. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 241. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 242. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 243. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 244. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 245. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 246. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 247. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 248. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 249. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 250. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 251. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 252. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 253. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 254. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 255. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 256. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 257. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 258. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 259. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 260. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 261. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 262. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 263. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 264. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 265. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 266. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 267. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 268. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 269. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 270. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 271. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 272. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 273. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 274. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 275. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 276. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 277. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 278. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 279. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 280. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 281. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 282. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 283. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 284. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 285. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 286. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 287. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 288. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 289. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 290. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 291. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 292. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 293. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 294. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 295. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 296. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 297. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 298. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 299. NETHERLANDS

[187 Pages Report] The Next-Generation Cancer Diagnostics Market size was estimated at USD 9.77 billion in 2023 and expected to reach USD 12.02 billion in 2024, at a CAGR 24.12% to reach USD 44.36 billion by 2030.

The next-generation cancer diagnostics market encompasses the latest technological advancements in the tools, techniques, and methodologies utilized to detect and characterize cancers. This market focuses on innovations that offer enhanced accuracy, sensitivity, and specificity compared to traditional diagnostic methods. It includes genomic, proteomic, and epigenomic analysis, imaging techniques, and bioinformatics tools for early detection, prognosis, and cancer treatment monitoring. Several factors drive the expansion of next-generation cancer diagnostics, including the increasing global prevalence of cancer, advancements in genomic sequencing technologies, and the growing emphasis on personalized medicine. Furthermore, government initiatives and funding for cancer research contribute significantly to market growth. Integrating artificial intelligence and machine learning in diagnostics also presents opportunities for enhanced precision in cancer detection and prognosis. Despite the promising development, the next-generation cancer diagnostics market faces several limitations and challenges. High costs associated with advanced diagnostic technologies can limit access to these tools, particularly in low- and middle-income countries. Moreover, the complexity of cancer biology and the variability in tumor types pose challenges in developing universally effective diagnostic solutions. Regulatory hurdles and the need for robust clinical validation also slow down the market's pace of innovation. However, recent developments in liquid biopsy, circulating tumor DNA (ctDNA) analysis, and non-invasive imaging techniques have opened new avenues for early cancer detection and monitoring. These advancements present significant opportunities for market growth. Moreover, the application of next-generation sequencing (NGS) in cancer diagnostics continues to evolve, offering the potential to discover novel biomarkers and therapeutic targets.

Technology: Increasing demand across molecular diagnostics to identify mutations associated with cancer

Clustered regularly interspaced short palindromic repeats diagnostics technology presents a revolutionary approach to cancer diagnostics, leveraging its gene editing capabilities to detect cancer mutations precisely. This technique offers the potential for rapid, accurate, and cost-effective diagnostics, fundamentally changing how cancers are identified and treated. DNA microarrays enable the simultaneous analysis of thousands of DNA sequences in a single experiment. This technology is used in cancer diagnostics to identify gene mutations and expressions specific to different cancer types, facilitating personalized treatment plans. Lab-on-a-chip integrates multiple laboratory processes into a single chip, offering a compact and efficient solution for cancer diagnostics. Combined with RT-PCR, a method that measures gene expression, it provides a powerful tool for detecting and quantifying cancer markers at the molecular level. Molecular diagnostics involves analyzing DNA or RNA sequences to identify cancer-related mutations. This segment emphasizes the importance of genetic analysis in the early detection, classification, and management of cancer, offering a tailored approach to therapy. NGS offers comprehensive genomic profiling by sequencing millions of DNA fragments in parallel. This technology provides deep insights into the genetic mutations that cause cancer, allowing for the identification of targeted therapies and better outcomes for patients. Protein microarrays analyze the expression and interaction of proteins on a large scale. In cancer diagnostics, they are used to study protein changes caused by cancer, aiding in discovering new biomarkers for early detection and treatment strategies. Quantitative Polymerase Chain Reaction (qPCR) is a technique that amplifies and quantifies a targeted DNA molecule. Multiplexing, simultaneously measuring multiple analytes, enhances qPCR's capability in cancer diagnostics, allowing for detecting multiple genes associated with cancer in a single test.

Application: Deployment of diagnostic tools across therapeutic monitoring to track the effectiveness of cancer treatments

Cancer screening represents the first line of defense in combating cancer, utilizing next-generation diagnostic technologies to identify the presence of cancer in individuals showing no apparent symptoms. This segment focuses on early cancer detection, aiming to diagnose diseases at a stage where they are more likely to be treated successfully. Advanced imaging technologies, molecular diagnostics, and biomarker assessment are tools used to enhance cancer screening efficacy. Companion diagnostics are specialized tests designed to identify patients most likely to benefit from a targeted therapy. This segment plays a critical role in personalized medicine by determining the presence of specific genetic or molecular markers that predict how well a patient will respond to targeted therapy options. In the context of next-generation cancer diagnostics, this often involves using genomic profiling to tailor treatment strategies to the individual's cancer. Prognostic tools in next-generation cancer diagnostics are employed to predict cancer's likely course and outcome in diagnosed patients. This segment helps in assessing disease aggression, the risk of recurrence, and overall survival expectations. By leveraging advanced genomic and proteomic analysis, prognostic diagnostics aid in making informed decisions regarding the necessity and intensity of therapeutic interventions, ultimately guiding patient management plans. Risk analysis in next-generation cancer diagnostics focuses on assessing an individual's risk of developing cancer based on genetic, environmental, and lifestyle factors. This segment utilizes various genetic testing and biomarker evaluation methods to identify individuals at higher risk for developing specific cancers, potentially leading to targeted preventive measures or more frequent and detailed surveillance programs. Therapeutic monitoring involves using next-generation diagnostic tools to track the effectiveness of cancer treatments and monitor for signs of disease progression or recurrence. This application segment is crucial for adjusting treatment plans in real time, managing side effects, and improving patient outcomes. Through the employment of circulating tumor DNA (ctDNA), imaging technologies, and other biomarkers, therapeutic monitoring provides detailed insights into the tumor's response to treatment and facilitates personalized treatment adjustments.

Regional Insights

In the Americas, particularly the United States, next-generation cancer diagnostics are experiencing rapid advancements, largely driven by significant investments in research and development. The focus is largely on precision medicine and non-invasive diagnostic techniques, such as liquid biopsies that detect circulating tumor DNA. The EMEA region shows a diverse landscape in adopting and developing next-generation cancer diagnostics. Europe leads within the region, with several countries incorporating genomic sequencing and biomarker analysis into standard cancer care, supported by strong healthcare systems and public healthcare policies. The Middle East, particularly countries such as Israel and the United Arab Emirates, are rapidly emerging as innovative hubs for medical technology, including cancer diagnostics. Africa faces more challenges, including resource limitations, but progress is being made through international partnerships and initiatives to improve cancer care infrastructure and accessibility. The Asia-Pacific region is witnessing significant growth in the next-generation cancer diagnostics market, driven by rising cancer prevalence, growing healthcare expenditure, and a surge in awareness about early cancer detection. Japan, South Korea, China, and Australia are at the forefront, investing heavily in healthcare technology and research. China, in particular, has seen rapid advancements and high adoption rates of technologies such as AI-driven diagnostic tools. Additionally, the region benefits from several fast-growing biotech startups and strategic collaborations between global and local firms aiming to tailor cancer diagnostics to regional specificities.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Next-Generation Cancer Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Next-Generation Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agena Bioscience, Inc. by Mesa Laboratories, Inc., Agilent Technologies, Inc., Akadeum Life Sciences, Almac Group, Becton, Dickinson & Company, Bio-Techne Corporation, Biological Dynamics Inc., bioMerieux SA, BioNTech SE, Castle Biosciences Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare, Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., NeoGenomics Laboratories, Novartis AG, OPKO Health, Inc., Oxford Nanopore Technologies Limited, Perkin Elmer, Inc., Qiagen N.V., Siemens Healthineers AG, Sysmex Corporation, Telerad Tech, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Technology
  • Clustered Regularly Interspaced Short Palindromic Repeats Diagnostics
  • DNA Microarrays
  • Lab-on-a-Chip & Reverse Transcriptase-PCR
  • Molecular Diagnostics
  • Next Generation Sequencing
  • Protein Microarrays
  • qPCR & Multiplexing

• Cancer Type
  • Bladder Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Kidney Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Thyroid Cancer
  • Uterine Cancer

• Application
  • Cancer Screening
  • Companion Diagnostics
  • Prognostics
  • Risk Analysis
  • Therapeutic Monitoring

• Function
  • Biomarker Development
  • CTC Analysis
  • Epigenetic Analysis
  • Genetic Analysis
  • Proteomic Analysis

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Next-Generation Cancer Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Next-Generation Cancer Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Next-Generation Cancer Diagnostics Market?

4. What is the market share of the leading vendors in the Next-Generation Cancer Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Next-Generation Cancer Diagnostics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Burden of Cancer Cases Globally and Need for Efficient Diagnostics
    • 5.1.1.2. Growing Utilization of Microfluidic Chips in Cancer Management
    • 5.1.1.3. Government Initiatives Towards Cancer Screening
  • 5.1.2. Restraints
    • 5.1.2.1. High Investment and Insufficient Standardization of Diagnostics
  • 5.1.3. Opportunities
    • 5.1.3.1. Proliferation of Personalized and Advanced Genome Medicine
    • 5.1.3.2. Technological Advancements in Next-Generation Cancer Diagnostics
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations and Risks Associated with NGC Diagnostics
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Increasing demand across molecular diagnostics to identify mutations associated with cancer
  • 5.2.2. Application: Deployment of diagnostic tools across therapeutic monitoring to track the effectiveness of cancer treatments
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis
• 5.9. Client Customization

6. Next-Generation Cancer Diagnostics Market, by Technology

• 6.1. Introduction
• 6.2. Clustered Regularly Interspaced Short Palindromic Repeats Diagnostics
• 6.3. DNA Microarrays
• 6.4. Lab-on-a-Chip & Reverse Transcriptase-PCR
• 6.5. Molecular Diagnostics
• 6.6. Next Generation Sequencing
• 6.7. Protein Microarrays
• 6.8. qPCR & Multiplexing

7. Next-Generation Cancer Diagnostics Market, by Cancer Type

• 7.1. Introduction
• 7.2. Bladder Cancer
• 7.3. Breast Cancer
• 7.4. Cervical Cancer
• 7.5. Colorectal Cancer
• 7.6. Kidney Cancer
• 7.7. Lung Cancer
• 7.8. Pancreatic Cancer
• 7.9. Prostate Cancer
• 7.10. Thyroid Cancer
• 7.11. Uterine Cancer

8. Next-Generation Cancer Diagnostics Market, by Application

• 8.1. Introduction
• 8.2. Cancer Screening
• 8.3. Companion Diagnostics
• 8.4. Prognostics
• 8.5. Risk Analysis
• 8.6. Therapeutic Monitoring

9. Next-Generation Cancer Diagnostics Market, by Function

• 9.1. Introduction
• 9.2. Biomarker Development
• 9.3. CTC Analysis
• 9.4. Epigenetic Analysis
• 9.5. Genetic Analysis
• 9.6. Proteomic Analysis

10. Americas Next-Generation Cancer Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Next-Generation Cancer Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Next-Generation Cancer Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Genialis to Develop Biomarker-Based Cancer Diagnostic Models
  • 13.3.2. Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell Therapies
  • 13.3.3. Pfizer shifts focus to oncology with USD 43 billion Seagen acquisition
  • 13.3.4. Ibex and Alverno Laboratories Sign Multi-Year, Multi-Tissue Expansion Agreement of AI for Cancer Diagnosis
  • 13.3.5. Swansea biotech startup raises £1.5m for AI bowel cancer blood test
  • 13.3.6. Precision for Medicine Accelerating Precision Oncology with Next Generation Screening to Support New Cancer Diagnostics

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio